ArticlePLoS computational biology2025
AI-driven discovery of novel extracellular matrix biomarkers in pelvic organ prolapse.
Article in PLoS computational biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tissue Biomarkers Outperform Plasma Signals in Pelvic Organ Prolapse: Evidence of a Dominant Extracellular Matrix Remodelling Phenotype.Current issues in molecular biology · 2026Article
- Network-informed multi-trait genomic analysis decodes the shared genetic architecture and therapeutic landscape of pelvic floor disorders.npj aging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Deep learning for protein function prediction faces significant challenges in identifying disease-specific proteins. We present Extracellular Matrix Protein Predictor (EPOP), an advanced transfer learning framework leveraging protein language models to decode disease mechanisms. Focusing on pelvic organ prolapse (POP), which affects up to 50% of women worldwide, EPOP demonstrates AI's power to reveal novel therapeutic targets. We developed a sophisticated fine-tuning protocol for the ESM-2 model, optimized for ECM protein prediction. Our architecture integrates specialized attention mechanisms with interpretability modules, trained on expertly curated and balanced datasets totaling 80,000 proteins (40,000 ECM and 40,000 non-ECM). The framework employs a novel validation strategy using a 16,000-sample independent test set and clinical proteomics data. EPOP achieved unprecedented performance (99.40% accuracy) in ECM protein classification, significantly surpassing traditional deep learning architectures (10.81% improvement over Transformer models, 21.71% over Long Short-Term Memory). Applied to clinical samples, our model revealed a previously unknown pattern of ECM remodeling, identifying 24 novel disease-associated proteins. Model interpretability analysis uncovered specific sequence motifs and structural features critical for ECM protein function, providing mechanistic insights into disease progression. EPOP demonstrates how advanced AI bridges molecular analysis and clinical applications, uncovering novel therapeutic targets. Its success suggests broader applications across ECM-related disorders, potentially transforming approaches to diseases affecting connective tissue architecture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.